The name of our company defines our services, strengths, and values. Since the inception, we have endeavoured to research, analyze and present the critical market data with great attention to details.
According to World Hemophilia Foundation report 2013, number of people identified with hemophilia was 176,211. It is estimated that only 30-40% of hemophilia patients are diagnosed. According to hemophilia journal 2012, bleeding disorders affect 1 in 1,000 men and women across the globe. Hemophilia A and B, and von Willebrand disease are the most prevalent bleeding disorders. In last few years, the number of hemophilic patients is increasing across the globe with India and Brazil reporting more newly diagnosed patients than the U.S. and U.K. The U.S. and Brazil reported the highest prevalence of over 4 per 100,000 populations. On the other hand, in India, numbers of prevalent cases were 0.9 per 100,000 populations. According to the U.S. Centers for Disease Control and Prevention, hemophilia occurs in approximately 1 in 5,000 live births. There are about 20,000 people with hemophilia in the U.S with races and ethnic groups are affected. Hemophilia A is four times more common as hemophilia B while more than half of patients with hemophilia A have the severe form of hemophilia.
After the epidemic resulting from the transmission of blood-borne viruses (hepatitis B virus, hepatitis C virus and human immunodeficiency virus), the need for safer hemophilia treatments became crucial to the hemophilia community. In this regard, recombinant factor VIII was first introduced in 1980s. In recent years, diagnosis rate of hemophilia and prophylactic treatment for hemophilia increased. These are the major factors for the growth of recombinant coagulation factors market. In addition, growing research on treatment of hemophilia is further expected to drive the growth. According to the recent study published by Meticulous Research®, the global recombinant coagulation factor market is expected to reach around $9,939.7 million in 2020 and grow at a CAGR of 7.6% during the forecast period of 2015 to 2020.
Browse full-In depth report on”Global Recombinant Coagulation Factors Market Outlook: 2015-2020″
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Meticulous Research® produces global reports and custom studies for North America, Europe, Latin America, Asia¬-Pacific, and Middle East and Africa regions. These reports are used by our clients for marketing and strategic planning in various sectors.
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Connect with us on Twitter- https://twitter.com/MeticulousR123
Meticulous Research– a leading global market research company published a research report titled “Ambulatory
Meticulous Research– a leading global market research company published a research report titled “Peripheral
Meticulous Research® – leading global market research company published a research report titled “Biomaterials